See also Editorial by Margaglione
B. Zöller (1), H. Ohlsson (1, 2), J. Sundquist (1, 2), K. Sundquist (1)
(1) Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, Sweden; (2) Stanford Prevention Research Center, Stanford University School of Medicine, Palo Alto, California, USA
Venous thromboembolism (VTE) clusters in families, but the familial risk of VTE has only been determined in first-degree relatives. This nationwide study aimed to determine the familial risk of VTE in first-, second- and third-degree relatives of affected individuals. The Swedish Multi-Generation Register was linked to Hospital Discharge Register data for the period 1987–2009. This was a case-cohort study. Odds ratios (ORs) for VTE were calculated for individuals whose relatives were hospitalised for VTE, as determined by the International Classification of Diseases (ICD), and those whose relatives were unaffected by VTE. The familial OR for VTE was 2.49 in siblings (95% confidence interval [CI] 2.40–2.58), 2.65 in children (2.50–2.80), 2.09 in parents (2.03–2.15), 1.52 in maternal half-siblings (1.26–1.85), 2.34 in paternal half-siblings (2.00–2.73), 1.69 in nieces/nephews (1.57–1.82), 1.47 in cousins (1.33–1.64), and 1.14 in spouses of individuals diagnosed with VTE (1.09–1.18). Familial clustering was stronger at young ages. The familial transmission was slightly stronger for males compared with females but was only significant for siblings 1.13 (1.05–1.22) and parents 1.11 (1.05–1.78) of probands. The present data showing an increased VTE risk among not only first-degree relatives but also second- and third-degree relatives indicate that the genetic component of the familial clustering of VTE is strong. Family history is a potentially useful genetic surrogate marker for clinical VTE risk assessment, even in second- and third degree-relatives.
Risk Factors, epidemiological studies, Deep venous thrombosis, thrombosis, thrombophilia
Folkert W. Asselbergs1, Scott M. Williams2, Patricia R. Hebert3, Christopher S. Coffey4, Hans L. Hillege1, Gerjan Navis5, Douglas E. Vaughan2, Wiek H. van Gilst1,6, Jason H. Moore7
Thromb Haemost 2006 96 4: 471-477
Karen Koopman1; Maarten Uyttenboogaart1; Patrick C. A. J. Vroomen1; Jan van der Meer2*; Jacques De Keyser1,3;
Thromb Haemost 2009 102 4: 620-622
N. Bauer, A. Moritz
Tierärztliche Praxis Kleintiere 2008 36 4: 235-246
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...